13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001381843
Total reported value
$371.7M
$371.7M
37 檔
22.1%
As reported in its official Q2 2025 Form 13F filing, Atle Fund Management AB's tracked investment portfolio stood at $371.7M with 37 total positions.
In Q2 2025, Atle Fund Management AB displayed an active expansion posture, initiating 1 new positions and adding to 23 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 12.92% | +0.95% | +11.90% | |
| 2 | ABBV | Abbvie Inc | Stock-Healthcare | 6.91% | +1.00% | -2.57% | |
| 3 | BSX | Boston Scientific CORP | Stock-Healthcare | 5.80% | -1.18% | -4.60% | |
| 4 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.75% | +0.77% | +16.49% | |
| 5 | MRK | Merck & Co. Inc. | Stock-Healthcare | 4.71% | -0.85% | +9.00% | |
| 6 | SYK | Stryker CORP | Stock-Healthcare | 4.65% | -0.53% | +19.43% | |
| 7 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 4.64% | -1.05% | +6.66% | |
| 8 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.32% | -0.41% | +20.94% | |
| 9 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 4.21% | -0.91% | +6.16% | |
| 10 | COR | Cencora Inc | Stock-Healthcare | 4.04% | +0.24% | -0.28% | |
| 11 | GILD | Gilead Sciences Inc | Stock-Healthcare | 3.47% | -0.74% | -4.98% | |
| 12 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.06% | -1.34% | +9.34% | |
| 13 | AMGN | Amgen Inc | Stock-Healthcare | 2.86% | -2.81% | EXIT | |
| 14 | ALKS | Alkermes plc | Stock-Healthcare | 2.78% | +0.35% | +5.79% | |
| 15 | ONC | Beone Medicines Ltd-adr | Stock-Other | 2.53% | -1.22% | -3.00% | |
| 16 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.33% | +0.15% | +38.37% | |
| 17 | UFPT | Ufp Technologies Inc | Stock-Other | 2.29% | — | +2.95% | |
| 18 | CAH | Cardinal Health Inc | Stock-Healthcare | 1.93% | -0.03% | -3.22% | |
| 19 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.92% | -0.16% | -3.91% | |
| 20 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.91% | — | +35.77% | |
| 21 | DXCM | Dexcom Inc | Stock-Healthcare | 1.90% | +0.45% | +10.97% | |
| 22 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 1.67% | -0.29% | +23.14% | |
| 23 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.45% | -0.71% | EXIT | |
| 24 | ✓ | Merus N V | Stock-Other | 1.35% | — | +69.70% | |
| 25 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.30% | +0.75% | +49.70% | |
| 26 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.22% | +0.49% | +45.87% | |
| 27 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 1.19% | +0.21% | -14.19% | |
| 28 | HRMY | Harmony Biosciences Holdings | Stock-Other | 1.17% | — | -5.51% | |
| 29 | AUTL | Autolus Therapeutics PLC | Stock-Other | 1.08% | — | +130.48% | |
| 30 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.06% | -0.90% | EXIT | |
| 31 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.89% | — | +96.13% | |
| 32 | SMMT | Summit Therapeutics Inc | Stock-Other | 0.84% | — | -11.74% | |
| 33 | ACLXGBX | Arcellx Inc | Stock-Other | 0.73% | — | -41.74% | |
| 34 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.59% | +0.41% | +22.99% | |
| 35 | IRON | Disc Medicine Inc | Stock-Other | 0.56% | -0.17% | — | |
| 36 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.52% | — | +78.61% | |
| 37 | JANX | Janux Therapeutics Inc | Stock-Other | 0.49% | — | +6.43% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NBIX | Neurocrine Biosciences Inc | +1% | +16.49% | Add |
| 2 | ISRG | Intuitive Surgical Inc | +1% | +20.94% | Add |
| 3 | VRNA | Verona Pharma PLC - Adr | +0.9% | +35.77% | Add |
| 4 | SYK | Stryker CORP | +0.9% | +19.43% | Add |
| 5 | MIRM | Mirum Pharmaceuticals Inc | +0.8% | +38.37% | Add |
| 6 | BBIO | Bridgebio Pharma Inc | +0.8% | +9.34% | Add |
| 7 | AUTL | Autolus Therapeutics PLC | +0.8% | +130.48% | Add |
| 8 | IRTC | Irhythm Holdings Inc | +0.7% | +23.14% | Add |
| 9 | ✓ | Merus N V | +0.7% | +69.70% | Add |
| 10 | IRON | Disc Medicine Inc | +0.6% | NEW | New buy |
| 11 | DXCM | Dexcom Inc | +0.5% | +10.97% | Add |
| 12 | MREO | Mereo Biopharma Group Pl-adr | +0.5% | +96.13% | Add |
| 13 | RVMD | Revolution Medicines Inc | +0.4% | +49.70% | Add |
| 14 | UFPT | Ufp Technologies Inc | +0.4% | +2.95% | Add |
| 15 | LLY | Eli Lilly & Co | +0.3% | +11.90% | Add |
| 16 | CRBP | Corbus Pharmaceuticals Holdi | +0.3% | +78.61% | Add |
| 17 | SLNOEUR | Soleno Therapeutics Inc | +0.3% | +9.26% | Add |
| 18 | CAH | Cardinal Health Inc | +0.3% | -3.22% | Trim |
| 19 | NAMS | NewAmsterdam Pharma Company N.V. | +0.3% | +45.87% | Add |
| 20 | COR | Cencora Inc | +0.2% | -0.28% | Trim |
| 21 | EW | Edwards Lifesciences CORP | 0% | -3.91% | Trim |
| 22 | SMMT | Summit Therapeutics Inc | -0.1% | -11.74% | Trim |
| 23 | JANX | Janux Therapeutics Inc | -0.1% | +6.43% | Add |
| 24 | BSX | Boston Scientific CORP | -0.1% | -4.60% | Trim |
| 25 | BCAX | Bicara Therapeutics Inc | -0.1% | +22.99% | Add |
| 26 | CABA | Cabaletta Bio Inc | -0.1% | EXIT | Sold out |
| 27 | HRMY | Harmony Biosciences Holdings | -0.2% | -5.51% | Trim |
| 28 | VRTX | Vertex Pharmaceuticals Inc | -0.2% | +6.66% | Add |
| 29 | GILD | Gilead Sciences Inc | -0.3% | -4.98% | Trim |
| 30 | MRK | Merck & Co. Inc. | -0.3% | +9.00% | Add |
| 31 | ALKS | Alkermes plc | -0.4% | +5.79% | Add |
| 32 | ONC | Beone Medicines Ltd-adr | -0.5% | -3.00% | Trim |
| 33 | ACLXGBX | Arcellx Inc | -0.6% | -41.74% | Trim |
| 34 | KRYS | Krystal Biotech Inc | -0.7% | -14.19% | Trim |
| 35 | AMGN | Amgen Inc | -0.8% | -10.10% | Trim |
| 36 | TMO | Thermo Fisher Scientific Inc | -0.8% | +6.16% | Add |
| 37 | ABBV | Abbvie Inc | -1.3% | -2.57% | Trim |
| 38 | UNH | Unitedhealth Group Inc | -4.9% | -46.76% | Trim |
According to official SEC Form 13F filings, Atle Fund Management AB reported a total U.S. public equity portfolio value of $371.7M across 37 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, ABBV, BSX) accounted for 22.1% of total reported equity market value during Q2 2025.
Top New Position Initiated
IRON
市值: $1.3M
Top Position Liquidated / Trimmed
CABA
前期市值: $252.6K
During Q2 2025, Atle Fund Management AB's top holdings by market value included LLY (12.9%)、ABBV (6.9%)、BSX (5.8%). The largest single position, LLY, represented 12.9% of total portfolio value.
In Q2 2025, Atle Fund Management AB made 38 total portfolio adjustments, initiating 1 new buys, adding to 23 positions, trimming 13 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.